17.	SEGMENT AND RELATED INFORMATION

The Company’s business units have been changed to align with how its Chief Operating Decision Maker (“CODM”) reviews performance and makes decisions in managing the Company. The business units were historically comprised of three reportable segments: (i) research, (ii) molecular diagnostics and (iii) pharmaceutical and clinical services. Beginning in fiscal 2015 the business units have been aggregated into two reportable segments: (i) diagnostics and (ii) other, which was formerly the research and pharmaceutical and clinical services segments. The diagnostics segment primarily provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology. Prior periods presented have been recast to conform to the current presentation.

The accounting policies of the segments are the same as those described in the summary of significant accounting policies (Note 1). The Company evaluates segment performance based on income (loss) before interest income and other income and expense.

	Diagnostics		Other			Total
Year ended June 30, 2017:
Revenues	$	722.1	$	49.3		$	771.4
Depreciation and amortization		42.8		5.5			48.3
Segment operating income (loss)		130.9		(81.5	)		49.4
Year ended June 30, 2016:
Revenues	$	705.7	$	48.1		$	753.8
Depreciation and amortization		21.5		5.2			26.7
Segment operating income (loss)		239.3		(72.5	)		166.8
Year ended June 30, 2015:
Revenues	$	695.5	$	27.6		$	723.1
Depreciation and amortization		20.5		4.5			25.0
Segment operating income (loss)		217.1		(82.9	)		134.2

	Years Ended June 30,
	2017			2016			2015
Total operating income for reportable segments	$	49.4		$	166.8		$	134.2
Unallocated amounts:
Interest income		1.2			0.9			0.4
Interest Expense		(6.0	)		(0.3	)		(0.2	)
Change in the fair value of contingent consideration		0.8			—			—
Other		(2.5	)		1.5			0.5
Income from operations before income taxes		42.9			168.9			134.9
Income tax provision		21.3			43.6			54.7
Net income		21.6			125.3			80.2
Net loss attributable to non-controlling interest		(0.2	)		—			—
Net income attributable to Myriad Genetics, Inc. stockholders	$	21.8		$	125.3		$	80.2

The following table sets forth a comparison of balance sheet assets by operating segment:

	June 30,
	2017		2016
Net equipment, leasehold improvements and property:
Diagnostics		20.2		26.3
Other		30.9		32.0
Total	$	51.1	$	58.3
Total Assets:
Diagnostics		900.9		512.4
Other		124.3		129.2
Total	$	1,025.2	$	641.6

The following table reconciles assets by geographical region:

	June 30,
	2017		2016
Net equipment, leasehold improvements and property:
United States		27.6		33.6
Rest of world		23.5		24.7
Total	$	51.1	$	58.3
Total Assets:
United States		912.8		532.6
Rest of world		112.4		109.0
Total	$	1,025.2	$	641.6

The following table reconciles assets by operating segment and geographic region to total assets:

	June 30,
	2017		2016
Total assets by segment and geographical region	$	1,025.2	$	641.6
Cash, cash equivalents, and marketable investment securities (1)		199.2		238.9
Total	$	1,224.4	$	880.5

(1)	The Company manages cash, cash equivalents, and marketable investment securities at the consolidated level for all segments

The majority of the Company’s revenues were derived from the sale of diagnostic tests in the United States. There were no customers that accounted for greater than 10% of revenue in the years ended June 30, 2017, 2016 and 2015.